{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T11:34:14Z","timestamp":1683286454560},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"St. Elisabeth Gruppe GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>In Deutschland kommt es immer wieder zu Masernausbr\u00fcchen. Patienten mit chronisch entz\u00fcndlichen Erkrankungen werden oft immunsuppressiv behandelt. In einer aktuellen Studie zeigte sich, dass etwa 7\u202f% dieser Patienten keinen Schutz gegen Maserninfektion haben. Das ergab sich aus der fehlenden Dokumentation im Impfausweis bzw. dem nicht vorhandenen Nachweis von protektiven Antik\u00f6rpern. Die St\u00e4ndige Impfkommission (STIKO) empfiehlt eine erste Impfung gegen Masern als Masern-Mumps-R\u00f6teln-Kombinationsimpfung (MMR) bei Kindern im Alter von 11\u201314 Monaten und eine zweite Impfung im Alter von 14\u201323 Monaten. F\u00fcr nach 1970 geborene Erwachsene wird eine Impfung gegen Masern empfohlen, wenn diese noch nicht bzw. nur einmal gegen Masern geimpft wurden oder wenn ihr Impfstatus unklar ist. Im April 2019 hat die STIKO Anwendungshinweise zu den bei Immundefizienz empfohlenen Impfungen ver\u00f6ffentlicht. Seit dem 1. M\u00e4rz 2020 besteht in Deutschland zudem eine Masernimpfpflicht.<\/jats:p>","DOI":"10.1007\/s00393-020-00877-1","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T09:04:34Z","timestamp":1600419874000},"page":"922-928","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ist komplette Immunit\u00e4t gegen Masern bei Patienten mit rheumatischen Erkrankungen ein realistisches Ziel, und wie ist es m\u00f6glicherweise zu erreichen?"],"prefix":"10.1007","volume":"79","author":[{"given":"J.","family":"Braun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Kiltz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"877_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-020-00874-4","author":"U Kiltz","year":"2020","unstructured":"Kiltz\u00a0U, Celik\u00a0A, Tsiami\u00a0S, Baraliakos\u00a0X, Andreica\u00a0I, Kiefer\u00a0D, B\u00fchring\u00a0B, Braun\u00a0J (2020) Wie gut sind Patienten mit entz\u00fcndlich rheumatischen Erkrankungen gegen Masern gesch\u00fctzt? Z\u00a0Rheumatol. https:\/\/doi.org\/10.1007\/s00393-020-00874-4","journal-title":"Z Rheumatol"},{"key":"877_CR2","first-page":"335","volume":"34","author":"RKI","year":"2018","unstructured":"RKI (2018) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiol Bull 34:335\u2013382","journal-title":"Epidemiol Bull"},{"issue":"6","key":"877_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00103-017-2555-4","volume":"60","author":"T Niehues","year":"2017","unstructured":"Niehues\u00a0T, Bogdan\u00a0C, Hecht\u00a0J, Mertens\u00a0T, Wiese-Posselt\u00a0M, Zepp\u00a0F (2017) Impfen bei Immundefizienz: Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen (I) Grundlagenpapier. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 60(6):674\u2013684","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"4","key":"877_CR4","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00103-019-02905-1","volume":"62","author":"N Wagner","year":"2019","unstructured":"Wagner\u00a0N, Assmus\u00a0F, Arendt\u00a0G, Baum\u00a0E, Baumann\u00a0U, Bogdan\u00a0C, Burchard\u00a0G, F\u00f6ll\u00a0D, Garbe\u00a0E, Hecht\u00a0J, M\u00fcller-Ladner\u00a0U, Niehues\u00a0T, \u00dcberla\u00a0K, Vygen-Bonnet\u00a0S, Weinke\u00a0T, Wiese-Posselt\u00a0M, Wojcinski\u00a0M, Zepp\u00a0F (2019) Impfen bei Immundefizienz: Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entz\u00fcndlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 62(4):494\u2013515","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"4","key":"877_CR5","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jaci.2013.11.043","volume":"133","author":"WT Shearer","year":"2014","unstructured":"Shearer\u00a0WT, Fleisher\u00a0TA, Buckley\u00a0RH et\u00a0al (2014) Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J\u00a0Allergy Clin Immunol 133(4):961\u2013966","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"877_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.2217\/IMT.15.74","volume":"7","author":"MM Eibl","year":"2015","unstructured":"Eibl\u00a0MM, Wolf\u00a0HM (2015) Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. Immunotherapy 7(12):1273\u20131292","journal-title":"Immunotherapy"},{"key":"877_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jbspin.2015.08.008","volume":"83","author":"J Morel","year":"2016","unstructured":"Morel\u00a0J, Czitrom\u00a0SG, Mallick\u00a0A, Sellam\u00a0J, Sibilia\u00a0J (2016) Vaccinations in adults with chronic inflammatory joint disease: immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs. Joint Bone Spine 83:135\u2013141","journal-title":"Joint Bone Spine"},{"key":"877_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaut.2017.03.011","volume":"80","author":"A Lopez","year":"2017","unstructured":"Lopez\u00a0A, Mariette\u00a0X, Bachelez\u00a0H et\u00a0al (2017) Vaccination recommendations for the adult immunosuppressed patient: a systematic review and comprehensive field synopsis. J\u00a0Autoimmun 80:10\u201327","journal-title":"J Autoimmun"},{"issue":"7","key":"877_CR9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/acr.22246","volume":"66","author":"C Hua","year":"2014","unstructured":"Hua\u00a0C, Barnetche\u00a0T, Combe\u00a0B, Morel\u00a0J (2014) Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a\u00a0systematic review and meta-analysis. Arthritis Care Res (Hoboken) 66(7):1016\u20131026","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"877_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/annrheumdis-2013-204020","volume":"74","author":"AB Aga","year":"2015","unstructured":"Aga\u00a0AB, Lie\u00a0E, Uhlig\u00a0T et al (2015) Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000\u20132010. Ann Rheum Dis 74:381\u2013388","journal-title":"Ann Rheum Dis"},{"key":"877_CR11","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1002\/art.10524","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran\u00a0MF, Crowson\u00a0CS, Pond\u00a0GR, O\u2019Fallon\u00a0WM, Gabriel\u00a0SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a\u00a0population-based study. Arthritis Rheum 46:2287\u20132293","journal-title":"Arthritis Rheum"},{"key":"877_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/annrheumdis-2013-204021","volume":"74","author":"J Listing","year":"2015","unstructured":"Listing\u00a0J, Kekow\u00a0J, Manger\u00a0B et\u00a0al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNF\u03b1 inhibitors and rituximab. Ann Rheum Dis 74:415\u2013421","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"877_CR13","doi-asserted-by":"publisher","first-page":"e001041","DOI":"10.1136\/rmdopen-2019-001041","volume":"5","author":"V Furer","year":"2019","unstructured":"Furer\u00a0V, Rondaan\u00a0C, Heijstek\u00a0M, van Assen\u00a0S, Bijl\u00a0M, Agmon-Levin\u00a0N, Breedveld\u00a0FC, D\u2019Amelio\u00a0R, Dougados\u00a0M, Kapetanovic\u00a0MC, van Laar\u00a0JM, Ladefoged de Thurah\u00a0A, Landew\u00e9\u00a0R, Molto\u00a0A, M\u00fcller-Ladner\u00a0U, Schreiber\u00a0K, Smolar\u00a0L, Walker\u00a0J, Warnatz\u00a0K, Wulffraat\u00a0NM, Elkayam\u00a0O (2019) Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a\u00a0systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 5(2):e1041","journal-title":"RMD Open"},{"issue":"2","key":"877_CR14","doi-asserted-by":"publisher","first-page":"e001035","DOI":"10.1136\/rmdopen-2019-001035","volume":"5","author":"C Rondaan","year":"2019","unstructured":"Rondaan\u00a0C, Furer\u00a0V, Heijstek\u00a0MW, Agmon-Levin\u00a0N, Bijl\u00a0M, Breedveld\u00a0FC, D\u2019Amelio\u00a0R, Dougados\u00a0M, Kapetanovic\u00a0MC, van Laar\u00a0JM, Ladefoged de Thurah\u00a0A, Landew\u00e9\u00a0R, Molto\u00a0A, M\u00fcller-Ladner\u00a0U, Schreiber\u00a0K, Smolar\u00a0L, Walker\u00a0J, Warnatz\u00a0K, Wulffraat\u00a0NM, van Assen\u00a0S, Elkayam\u00a0O (2019) Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a\u00a0systematic literature review for the 2019 update of EULAR recommendations. RMD Open 5(2):e1035","journal-title":"RMD Open"},{"issue":"1","key":"877_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer\u00a0V, Rondaan\u00a0C, Heijstek\u00a0MW, Agmon-Levin\u00a0N, van Assen\u00a0S, Bijl\u00a0M, Breedveld\u00a0FC, D\u2019Amelio\u00a0R, Dougados\u00a0M, Kapetanovic\u00a0MC, van Laar\u00a0JM, de Thurah\u00a0A, Landew\u00e9\u00a0RB, Molto\u00a0A, M\u00fcller-Ladner\u00a0U, Schreiber\u00a0K, Smolar\u00a0L, Walker\u00a0J, Warnatz\u00a0K, Wulffraat\u00a0NM, Elkayam\u00a0O (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39\u201352","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"877_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/infdis\/159.4.610","volume":"159","author":"P Ljungman","year":"1989","unstructured":"Ljungman\u00a0P, Fridell\u00a0E, L\u00f6nnqvist\u00a0B, Bolme\u00a0P, B\u00f6ttiger\u00a0M, Gahrton\u00a0G, Linde\u00a0A, Ringd\u00e9n\u00a0O, Wahren\u00a0B (1989) Efficacy and safety of vaccination of marrow transplant recipients with a\u00a0live attenuated measles, mumps, and rubella vaccine. J\u00a0Infect Dis 159(4):610\u2013615","journal-title":"J Infect Dis"},{"issue":"2","key":"877_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/rheumatology\/ken436","volume":"48","author":"S Borte","year":"2009","unstructured":"Borte\u00a0S, Liebert\u00a0UG, Borte\u00a0M, Sack\u00a0U (2009) Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 48(2):144\u2013148","journal-title":"Rheumatology (Oxford)"},{"issue":"23","key":"877_CR18","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1001\/jama.2013.6768","volume":"309","author":"MW Heijstek","year":"2013","unstructured":"Heijstek\u00a0MW, Kamphuis\u00a0S, Armbrust\u00a0W, Swart\u00a0J, Gorter\u00a0S, de Vries\u00a0LD, Smits\u00a0GP, van Gageldonk\u00a0PG, Berbers\u00a0GA, Wulffraat\u00a0NM (2013) Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a\u00a0randomized trial. JAMA 309(23):2449\u20132456","journal-title":"JAMA"},{"issue":"12","key":"877_CR19","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.vaccine.2015.01.075","volume":"33","author":"Y Kawano","year":"2015","unstructured":"Kawano\u00a0Y, Suzuki\u00a0M, Kawada\u00a0J, Kimura\u00a0H, Kamei\u00a0H, Ohnishi\u00a0Y, Ono\u00a0Y, Uchida\u00a0H, Ogura\u00a0Y, Ito\u00a0Y (2015) Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients. Vaccine 33(12):1440\u20131445","journal-title":"Vaccine"},{"issue":"16","key":"877_CR20","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1016\/j.vaccine.2006.01.028","volume":"24","author":"F Del Porto","year":"2006","unstructured":"Del Porto\u00a0F, Lagan\u00e0\u00a0B, Biselli\u00a0R, Donatelli\u00a0I, Campitelli\u00a0L, Nisini\u00a0R, Cardelli\u00a0P, Rossi\u00a0F, D\u2019Amelio\u00a0R (2006) Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine 24(16):3217\u20133223","journal-title":"Vaccine"},{"key":"877_CR21","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/ard.2005.043943","volume":"65","author":"A Holvast","year":"2006","unstructured":"Holvast\u00a0A, Huckriede\u00a0A, Wilschut\u00a0J et\u00a0al (2006) Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 65:913\u2013918","journal-title":"Ann Rheum Dis"},{"key":"877_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tax082","author":"F Huber","year":"2018","unstructured":"Huber\u00a0F, Ehrensperger\u00a0B, Hatz\u00a0C, Chappuis\u00a0F, B\u00fchler\u00a0S, Eperon\u00a0G (2018) Safety of live vaccines on immunosuppressive or immunomodulatory therapy\u2011a retrospective study in three Swiss Travel Clinics. J\u00a0Travel Med. https:\/\/doi.org\/10.1093\/jtm\/tax082","journal-title":"J Travel Med"},{"issue":"7","key":"877_CR23","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.vaccine.2019.12.024","volume":"38","author":"L Cagol","year":"2020","unstructured":"Cagol\u00a0L, Seitel\u00a0T, Ehrenberg\u00a0S, Frivolt\u00a0K, Krahl\u00a0A, Lainka\u00a0E, Gerner\u00a0P, Lenhartz\u00a0H, Vermehren\u00a0J, Radke\u00a0M, Trenkel\u00a0S, Mayer\u00a0B, Koletzko\u00a0S, Debatin\u00a0KM, Mertens\u00a0T, Posovszky\u00a0C (2020) Vaccination rate and immunity of children and adolescents with inflammatory bowel disease or autoimmune hepatitis in Germany. Vaccine 38(7):1810\u20131817","journal-title":"Vaccine"},{"key":"877_CR24","first-page":"30052","volume":"24","author":"Y Uziel","year":"2020","unstructured":"Uziel\u00a0Y, Moshe\u00a0V, Onozo\u00a0B, Kulcs\u00e1r\u00a0A, Tr\u00f3bert-Sipos\u00a0D, Akikusa\u00a0JD, Salviato Pileggi\u00a0G, Maritsi\u00a0D, Kasapcopur\u00a0O, Rodrigues\u00a0M, Smerla\u00a0R, Rigante\u00a0D, Makay\u00a0B, Atsali\u00a0E, Wulffraat\u00a0N, Toplak\u00a0N (2020) Live attenuated MMR\/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection. Vaccine 24:30052\u201330059","journal-title":"Vaccine"},{"key":"877_CR25","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1136\/annrheumdis-2016-209562","volume":"76","author":"D Lacaille","year":"2017","unstructured":"Lacaille\u00a0D, Avina-Zubieta\u00a0JA, Sayre\u00a0EC, Abrahamowicz\u00a0M (2017) Improvement in 5\u2011year mortality in incident rheumatoid arthritis compared with the general population\u2014Closing the mortality gap. Ann Rheum Dis 76:1057\u20131063","journal-title":"Ann Rheum Dis"},{"key":"877_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.berh.2015.05.009","volume":"29","author":"M Lahiri","year":"2015","unstructured":"Lahiri\u00a0M, Dixon\u00a0W (2015) Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol 29:290\u2013305","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"s40","key":"877_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"2","author":"KL Winthrop","year":"2018","unstructured":"Winthrop\u00a0KL, Mariette\u00a0X, Silva\u00a0JT et\u00a0al (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2(s40):21","journal-title":"Clin Microbiol Infect"},{"key":"877_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.trsl.2015.08.008","volume":"167","author":"JE McKinnon","year":"2016","unstructured":"McKinnon\u00a0JE, Maksimowicz-McKinnon\u00a0K (2016) Autoimmune disease and vaccination: impact on infectious disease prevention and a\u00a0look at future applications. Transl Res 167:46\u201360","journal-title":"Transl Res"},{"key":"877_CR29","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1177\/1352458510394397","volume":"17","author":"M Oikonen","year":"2011","unstructured":"Oikonen\u00a0M, Laaksonen\u00a0M, Aalto\u00a0V et al (2011) Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence. Mult Scler 17:672\u2013680","journal-title":"Mult Scler"},{"key":"877_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0022-510X(98)00139-7","volume":"159","author":"J De Keyser","year":"1998","unstructured":"De Keyser\u00a0J, Zwanikken\u00a0C, Boon\u00a0M (1998) Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J\u00a0Neurol Sci 159:51\u201353","journal-title":"J Neurol Sci"},{"key":"877_CR31","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.1016\/j.vaccine.2010.07.039","volume":"28","author":"N Bakare","year":"2010","unstructured":"Bakare\u00a0N, Menschik\u00a0D, Tiernan\u00a0R, Hua\u00a0W, Martin\u00a0D (2010) Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine 28:6609\u20136612","journal-title":"Vaccine"},{"key":"877_CR32","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/INF.0000000000000788","volume":"34","author":"B Morillo-Gutierrez","year":"2015","unstructured":"Morillo-Gutierrez\u00a0B, Worth\u00a0A, Valappil\u00a0M, Gaspar\u00a0HB, Gennery\u00a0AR (2015) Chronic infection with Rotavirus vaccine strains in UK children with severe combined Immunodeficiency. Pediatr Infect Dis\u00a0J 34:1040\u20131041","journal-title":"Pediatr Infect Dis J"},{"key":"877_CR33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/cid\/ciw675","volume":"64","author":"B Neven","year":"2017","unstructured":"Neven\u00a0B, Perot\u00a0P, Bruneau\u00a0J et\u00a0al (2017) Cutaneous and visceral chronic granulomatous disease triggered by a\u00a0rubella virus vaccine strain in children with primary Immunodeficiencies. Clin Infect Dis 64:83\u201386","journal-title":"Clin Infect Dis"},{"key":"877_CR34","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.jaci.2016.06.030","volume":"138","author":"L Perelygina","year":"2016","unstructured":"Perelygina\u00a0L, Plotkin\u00a0S, Russo\u00a0P et\u00a0al (2016) Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. J\u00a0Allergy Clin Immunol 138:1436\u20131439","journal-title":"J Allergy Clin Immunol"},{"key":"877_CR35","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1016\/j.vaccine.2015.06.012","volume":"33","author":"P Loubet","year":"2015","unstructured":"Loubet\u00a0P, Kerneis\u00a0S, Groh\u00a0M et\u00a0al (2015) Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a\u00a0large cohort of patients with secondary immunodeficiency. Vaccine 33:3703\u20133708","journal-title":"Vaccine"},{"key":"877_CR36","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.vaccine.2015.01.065","volume":"33","author":"I Hmamouchi","year":"2015","unstructured":"Hmamouchi\u00a0I, Winthrop\u00a0K, Launay\u00a0O, Dougados\u00a0M (2015) Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine 33:1446\u20131452","journal-title":"Vaccine"},{"key":"877_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJM200102013440501","volume":"344","author":"C Confavreux","year":"2001","unstructured":"Confavreux\u00a0C, Suissa\u00a0S, Saddier\u00a0P, Bourdes\u00a0V, Vukusic\u00a0S (2001) Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in multiple sclerosis study group. N\u00a0Engl J Med 344:319\u2013326","journal-title":"N Engl J Med"},{"key":"877_CR38","unstructured":"RKI (2020) Epidemiologisches Bulletin. https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2020\/Ausgaben\/02_20.pdf?__blob=publicationFile. Zugegriffen: 15.6.2020"},{"key":"877_CR39","unstructured":"Gesetz f\u00fcr den Schutz vor Masern und zur St\u00e4rkung der Impfpr\u00e4vention (Masernschutzgesetz) vom 10. Februar 2020. Bundesgesetzblatt Jahrgang 2020\u00a0Teil I Nr.\u00a06, ausgegeben zu Bonn am 13. Februar 2020"},{"key":"877_CR40","unstructured":"RKI (2015) Antworten auf h\u00e4ufig gestellte Fragen (FAQ) zum Thema Masern. Stand: 23.02.2015. https:\/\/www.rki.de\/SharedDocs\/FAQ\/MMR\/Masern\/Liste_Masern.html. Zugegriffen: 15.6.2020"},{"key":"877_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/epidemiologia2010001","volume":"2","author":"RKI","year":"2020","unstructured":"RKI (2020) Mitteilung der St\u00e4ndigen Impfkommission beim Robert Koch-Institut: Empfehlung und wissenschaftliche Begr\u00fcndung f\u00fcr die Angleichung der beruflich indizierten Masern-Mumps-R\u00f6teln-(MMR-) und Varizellen-Impfung. Epidemiol Bull 2:1\u201322","journal-title":"Epidemiol Bull"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00877-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-020-00877-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00877-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:20:51Z","timestamp":1631924451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-020-00877-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00877-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"15 May 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Braun, U.\u00a0Kiltz und U.\u00a0M\u00fcller-Ladner geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}